Table 2. Effect of spironolactone dosage (2 mg/kg/day vs. 4 mg/kg/day) on RAS-Fingerprint^™ analytes in 10 healthy purpose-bred Beagle dogs at combined baseline (D0 T1, D0 T2, D21 T1, and D21 T2) and post-treatment (D7 T1, D7 T2, D28 T1, and D28 T2) using a cross-over study design.

Data are presented as median (IQR) in pM/L for AngI, AngII, aldosterone, Ang1-7, Ang1-5, AngIII, AngIV, and PRA-S and as a ratio for ACE-S, AA2, and ALT-S. P value represents comparison of percent change from baseline between the two dosing groups.

RAS-Fingerprint™ analyte	Baseline	Post-treatment 2 mg/kg	Post-treatment 4 mg/kg	P-value for percent change from baseline between dose groups
AngI(1–10)	80.3 (50.6–127.8)	88.2 (66.2–129.8)	88.3 (61.5–119.0)	0.76
AngII(1–8)	37.0 (27.5–54.6)	47.7 (32.0–63.8)	41.3 (33.6–60.5)	0.76
Aldosterone	15.9 (8.7–41.2)	34.1 (11.5–83.0)	34.3 (16.3–52.6)	0.62
Ang1-7	18.0 (13.5–34.6)	24.3 (18.4–34.5)	25.9 (17.5–32.6)	0.24
Ang1-5	23.6 (16.4–42.5)	38.3 (22.8–53.0)	36.3 (22.1–55.5)	0.74
AngIII(2–8)	5.5 (4.1–10.5)	6.2 (4.6–11.9)	5.9 (4.2–10.6)	0.64
AngIV(3–8)	10.3 (6.7–18.1)	10.3 (8.0–19.8)	11.4 (8.1–16.2)	0.82
PRA-S	119.4 (82.9–177.9)	139.4 (97.6–192.4)	137.9 (92.6–174.8)	0.76
ACE-S	0.5 (0.4–0.6)	0.5 (0.5–0.6)	0.5 (0.5–0.6)	0.9
AA2	0.4 (0.2–1.0)	0.8 (0.3–1.3)	0.7 (0.3–1.2)	0.62
ALT-S	0.3 (0.29–0.31)	0.3 (0.2–0.3)	0.3 (0.3–0.4)	0.72